检索结果-南通市图书馆

Expert consensus guidelines on clinical use of Xiyanping injection for acute infectious diseases

Asian Pacific Journal of Tropical medicine 2020年第4期13卷 152-161页

作者： Banghan Ding Bangjiang Fang Jun Li Qingquan Liu Chuanzhu Lv Xuezhong Yu Xiaodong Zhao emergency branch of china association of chinese medicine chinese College of emergency Physicians of chinese Medical Doctor association emergency branch of World Federation chinese medicine Societies emergency branch of china association of Promoting Traditional medicine Key Laboratory of emergency and Trauma of Ministry of Education,Hainan Medical University Research Unit of Island emergency medicine,chinese Academy of Medical Sciences,Hainan Medical University Key Laboratory of Traditional chinese medicine for Prevention and Control of Infectious Diseases,Guangdong Province Traditional chinese Medical Hospital Guangdong Provincial Traditional chinese Medical Hospital Guangzhou 510120China Longhua Hospital Shanghai University of Traditional chinese medicine Shanghai 200032China Beijing Hospital of Traditional chinese medicine Beijing 100010China Hainan Medical University Haikou 570102China Peking Union Medical College Hospital Beijing 100730China Fourth Medical Center of PLA General Hospital Beijing 100010China 不详

Xiyanping injection,a traditional chinese medicine injection made of andrographolide sulfonate,consisting of well-defined ingredients with antiviral,antibacterial,anti-inflammatory and antipyretic efficacy,has been widely used for treating infectious diseases of respiratory and digestive ***,its wide applications may easily lead to unreasonable clinical *** order to guide the precise clinical application and rational use of Xiyanping injection,experts in related fields conducted systematically literature review,evaluated and deliberated the application of Xiyanping injection in treating acute infectious diseases using evidence-based medicine method,and jointly drafted the consensus to summarize types of acute infectious diseases in children and adults that can be treated with Xiyanping injection,and recommend the intervention time,usage and dosage,course of treatment and combined medication of the ***,the consensus elucidates the safety,precautions and contraindications of the injection,so as to provide guidance for clinical use.

关键词： Xiyanping injection Expert consensus Acute infectious diseases Evidence-based medicine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

百乐眠胶囊治疗失眠症临床应用专家共识

引用

中国中药杂志 2024年第20期 5635-5642页

作者： Expert Group of Psychosomatic medicine branch of china association of chinese medicine 中华中医药学会心身医学分会专家组

百乐眠胶囊作为适用于阴虚火旺型失眠症的中成药，目前被广泛应用于短期失眠症、慢性失眠症及卒中后失眠、失眠伴焦虑抑郁状态等心身疾病，并被多项共识/指南/路径推荐。该共识在专家访谈、问卷调研和百乐眠胶囊文献系统回顾的基础上，... 详细信息

百乐眠胶囊作为适用于阴虚火旺型失眠症的中成药，目前被广泛应用于短期失眠症、慢性失眠症及卒中后失眠、失眠伴焦虑抑郁状态等心身疾病，并被多项共识/指南/路径推荐。该共识在专家访谈、问卷调研和百乐眠胶囊文献系统回顾的基础上，遵循“循证为举，共识为主，经验为鉴”原则，总结现有最佳证据，充分结合专家经验以及患者偏好，基于百乐眠胶囊自身特点及临床实际，形成了百乐眠胶囊单用和联合西药用于治疗失眠症、慢性失眠症伴焦虑抑郁状态、特殊人群失眠症等7条推荐意见和12条共识建议。共识起草过程中，通过线上与线下相结合的征求意见方式，在全国范围内进行了征求意见和同行评议。该共识适用于各级医院的中医、西医和中西医结合医师，基层卫生服务机构的临床医师，为其合理使用百乐眠胶囊提供指导和参考。旨在指导和规范临床医生合理使用百乐眠胶囊，提高临床疗效和安全性。该共识已通过中华中医药学会审核发布，编号GS/CACM 329-2023。

关键词：百乐眠胶囊专家共识失眠症循证医学中医药

来源：

同方期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

chinese Clinical Practice Guidelines for the Prevention and Treatment of Mother-to-Child Transmission of Hepatitis B Virus(Version 2024)

引用

Infectious Microbes & Diseases 2024年第3期6卷 108-116页

作者： Jinfeng Liu Qinglei Zeng Fanpu Ji Hong Ren Wenhong Zhang Lanjuan Li Yingren Zhao Infectious Diseases Physicians branch of chinese Medical Doctor association chinese Society of Infectious Diseases of chinese Medical association The First Affiliated Hospital of Xi’an Jiaotong University Xi’anChina Shaanxi Clinical Medical Research Center of Infectious Diseases Xi’anChina The First Affiliated Hospital of Zhengzhou University ZhengzhouChina The Second Affiliated Hospital of Xi’an Jiaotong University Xi’anChina The Second Affiliated Hospital of Chongqing Medical University ChongqingChina Huashan Hospital Fudan UniversityShanghaiChina State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases The First Affiliated HospitalZhejiang University School of MedicineHangzhouChina 不详

The chinese Clinical Practice Guidelines for the prevention and treatment ofmother-to-child transmission of hepatitis B virus,developed by the chinese Society of Infectious Diseases of the chinese Medical association in 2019,serves as a valuable reference for standardizing the process of preventing mother-to-child transmission in *** new evidence emerges,it is crucial that timely and regular updates are made to the clinical practice guidelines so as to optimize guidance for clinical practice and *** this end,the Infectious Disease Physician branch of chinese Medical Doctor association and the chinese Society of Infectious Diseases of chinese Medical association,in collaboration with multidisciplinary experts,have updated the guidelines based on the latest domestic and international research advancements and clinical practice,in order to provide guidance and reference for clinicians andmaternal and child healthcare workers.

关键词： guidelines hepatitis B virus mother-to-child transmission prevention treatment update

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinical Management Guidelines for Intrahepatic Cholestasis of Pregnancy

引用

Maternal-Fetal medicine 2024年第1期6卷 13-22页

作者： Obstetrics Group of the Gynecology and Obstetrics branch of chinese Medical association Perinatal medicine branch of chinese Medical association Xinyang Yu Huixia Yang Hongbo Qi 不详 Medical University Chongqing 400016China Department of Obstetrics and Gynecology Peking University First HospitalBeijing 100034China Department of Obstetrics and Gynecology Women and Children's Hospital of Chongqing Medical UniversityChongqing 401147China

Intrahepatic cholestasis of pregnancy(ICP)is a significant gestational complication in late pregnancy,potentially leading to severe perinatal complications such as intrauterine fetal demise and preterm *** Obstetrics Group of the Gynecology and Obstetrics branch and the Perinatal medicine branch of the chinese Medical association organized a panel of domestic experts to deliberate and propose recommendations based on domestic and international guidelines,recent evidence-based medical evidence about key clinical issues including risk factors,clinical manifestations,perinatal outcomes,diagnosis,severity grading,maternal and fetal monitoring,treatment methods,timing,and methods of pregnancy termination,and postpartum follow-up for ICP,with the aim to guide its clinical diagnosis,treatment,and management.

关键词： Cholestasis,Intrahepatic Bile Acids Stillbirth Preterm Birth Diagnostic and Therapeutic Guidelines(Theme)

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

引用

chinese Journal of Cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Hospital Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Division of Therapeutic Drug Monitoring of chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of chinese Society of Clinical Oncology(CSCO) Expert Committee on Leukemia of chinese Society of Clinical Oncology(CSCO) Society of Integrative Cardio-Oncology of china Anti-Cancer association(CACA) chinese Society of Hematology of chinese Medical association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits medicine Exchange association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

2023 Guideline for the management of hypertension in the elderly population in china

引用

Journal of Geriatric Cardiology 2024年第6期21卷 589-630页

作者： Hypertension branch of chinese Geriatrics Society,Beijing Hypertension association,National Clinical Research Center of the Geriatric Diseases Qi HUA Li FAN Zeng-Wu WANG Jing LI 不详 Xuanwu Hospital Capital Medical UniversityBeijingChina chinese PLA General Hospital BeijingChina Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Preamble Hypertension is one of the most common chronic diseases and the primary risk factor for stroke,myocardial infarction and even cardiovascular *** than half of the elderly population has high blood *** people are a unique group,and strategies for the prevention,diagnosis,evaluation,and treatment of hypertension in elderly individuals differ significantly from those in the general population.

关键词： hypertension prevention diagnosis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer(2024 edition)

引用

Radiation medicine and Protection 2024年第2期5卷 59-67页

作者： Professional Committee of Radiation Oncology china Anti-Cancer association branch of Radiation Oncology chinese Medical association branch of Radiation Oncology TreatmentPhysician chinese Medical Doctor association Qingsong Pang Jun Wang Zhouguang Hui Wencheng Zhang 不详 Tianjin Medical University Cancer Institute&Hospital Tianjin 300060China the Fourth Hospital of Hebei Medical University Shijiazhuang 050011China National Cancer Center National Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Tianjin Medical University Cancer Hospital China

Radiotherapy represents an essential treatment approach for esophageal *** recent years,immunotherapy combined with chemotherapy has become the first-line standard treatment for patients with advanced esophageal *** phase III studies on immunotherapy combined with radiotherapy for locally advanced esophageal cancer are currently *** evidence-based medical data are urgently needed to support the integration of immunotherapy and chemoradiotherapy as a new treatment strategy for patients with locally advanced esophageal *** consensus,formulated based on the latest study results,in-depth research,and thorough discussions,provides a comprehensive set of *** document extensively covers treatment strategies and evaluation methods for radiotherapy combined with immunotherapy across patients with operable esophageal cancer,inoperable locally advanced esophageal cancer,and advanced esophageal ***,common complications and radiation-related issues associated with radiotherapy combined with immunotherapy are discussed,serving as clinical *** expert group comprised members from the Professional Committee of Radiation Oncology,china Anti-Cancer association,the branch of Radiation Oncology,chinese Medical association,and the branch of Radiation Oncology Treatment Physician,chinese Medical Doctor association.

关键词： Esophageal squamous cell carcinoma Esophageal adenocarcinoma Immunotherapy Chemoradiotherapy Radiotherapy Expert consensus

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

引用

Journal of Geriatric Cardiology 2024年第3期21卷 251-314页

作者： Chang-Sheng MA Shu-Lin WU Shao-Wen LIU Ya-Ling HAN chinese Society of Cardiology chinese Medical association Heart Rhythm Committee of chinese Society of Biomedical Engineering Beijing Anzhen Hospital Capital Medical University Guandong Provincial People’s Hospital Shanghai First People’s Hospital General Hospital of Northern Theater Command 不详

Atrial fibrillation(AF)is the most common sustained cardiac arrhythmia,significantly impacting patients’quality of life and increasing the risk of death,stroke,heart failure,and *** the past two decades,there have been significant breakthroughs in AF risk prediction and screening,stroke prevention,rhythm control,catheter ablation,and integrated *** this period,the scale,quality,and experience of AF management in china have greatly improved,providing a solid foundation for the development of guidelines for the diagnosis and management of *** further promote standardized AF management,and apply new technologies and concepts to clinical practice in a timely and comprehensive manner,the chinese Society of Cardiology of the chinese Medical association and the Heart Rhythm Committee of the chinese Society of Biomedical Engineering have jointly developed the chinese Guidelines for the Diagnosis and Management of Atrial *** guidelines have comprehensively elaborated on various aspects of AF management and proposed the CHA2DS2-VASc-60 stroke risk score based on the characteristics of AF in the Asian *** guidelines have also reevaluated the clinical application of AF screening,emphasized the significance of early rhythm control,and highlighted the central role of catheter ablation in rhythm control.

关键词： prevention sustained diagnosis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Stress Echocardiography for Chronic Coronary Syndrome:Clinical Practice Guidelines(2023)

引用

Journal of Geriatric Cardiology 2024年第5期21卷 475-505页

作者： Peng-Fei ZHANG Jia-Wei TIAN Tian-Gang ZHU Jue-Fei WU Xiao-Ping LENG Yi WANG Meng-Meng LI Xin-Hao LI Qian-Qian WANG Xiao-Peng FENG Jia-Yan LV Li-Xue YIN Yun ZHANG Mei ZHANG chinese Society of Echocardiography,Superficial Tissue and Vascular Group of chinese Society of Ultrasound in medicine,Ultrasound Professional Committee of chinese medicine Education association State Key Laboratory for Innovation and Transformation of Luobing Theory Key Laboratory of Cardiovascular Remodeling and Function ResearchChinese Ministry of EducationChinese National Health Commission and Chinese Academy of Medical SciencesDepartment of CardiologyQilu Hospital of Shandong UniversityJinanChina The Second Affiliated Hospital of Harbin Medical University HaerbinChina Peking University People's Hospital BeijingChina Sichuan Province People's Hospital ChengduChina Nanfang Hospital Southern Medical UniversityGuangzhouChina Peking Union Medical College Hospital Chinese Academy of Medical SciencesBeijingChina 不详

In the context of the People's Republic of china,coronary artery disease(CAD)presents a sig-nificant clinical challenge,with over 11.3 mil-lion patients ***,the diagnos-is of CAD has predominantly relied on invasive coronary angiography.[1]However,recent advances in clinical research have revealed a notable trend:a substantial 82% of patients subjected to such invas-ive diagnostics do not necessitate interventional therapy.

关键词： coronary clinical patients

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations(2023 edition)

引用

chinese Medical Journal 2024年第9期137卷 1016-1018页

作者： The Society of Cancer Precision medicine of chinese Anti-Cancer association The Lung Cancer Expert Group of chinese Medical association Publishing House Baohui Han Hua Zhong 不详 Department of Respiratory medicine Shanghai Chest HospitalSchool of MedicineShanghai JiaoTong UniversityShanghai 20030China Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine

Non-small cell lung cancer(NSCLC)with oncogenic driver mutations was previously deemed“forbidden territory”for immunotherapy.[1]With the continuous generation of evidence,immunotherapy is expected to bring hope for such NSCLC with oncogenic driver mutations after acquired tyrosine kinase inhibitor(TKI)***,given the intricate interplay between driven mutations,targeted therapy,and immune microenvironment,the efcacy of immunotherapy in advanced NSCLC patients with diverse oncogenic driver mutations remains a topic of ongoing *** this context,chinese Expert Consensus on Immunotherapy for Advanced NSCLC with Oncogenic Driver Mutations(2022 edition)wasrst launched in 2022 by the Society of Cancer Precision medicine of chinese Anti-Cancer association and the Lung Cancer Expert Group of chinese Medical Journals,aiming to provide standardized treatment guidance for clinical practice.

关键词： immunotherapy cancer lung

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：